Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

  • Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study
  • Sanofi intends to submit the data to support a regulatory application in the US for the treatment of infantile-onset Pompe disease